Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Are we halted ?

<< Previous

Bullboard Posts

Next >>

Comment by gebremeskelon Jan 26, 2023 5:18pm

185 Views

Post# 35248885

RE:RE:RE:RE:RE:RE:RE:Are we halted ?

Your belief about how TLD-1433 "deserved" to be trialled is beside the point. Did Theralase request this of the FDA and were not "permitted"? Or did Theralase submit the exact protocol they wanted to - for BCG-unresponsive NMIBC?

fredgoodwinson wrote: This reasoning is in the context of a belief (which I strongly expressed at the time of the Clinical Protocol) that on the basis of the preclinical evidence TLD-1433 deserved to be trialled as a first-line treatment against early stage disease. Many lesser prospects had and have been permitted this setting.

<< Previous

Bullboard Posts

Next >>

Honda to build Canada’s first EV supply chain for C$15 billion